Pfizer Inc. (PFE)

US — Healthcare Sector
Peers: GILD  SNY  AMGN  GSK  BMY  SYK  MRK  BSX  NVO  DHR 

Automate Your Wheel Strategy on PFE

With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Pfizer's Quiet Cash Comeback
PFE
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive

Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.

Read More
image for news Pfizer's Quiet Cash Comeback
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
PFE
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Neutral

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Read More
image for news Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
PFE
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Neutral

Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.

Read More
image for news Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Pfizer CEO flags issues with FDA's vaccine leadership
PFE
Published: March 02, 2026 by: Reuters
Sentiment: Negative

Pfizer CEO Albert ​Bourla on ‌Monday flagged issues ​with the ​leadership of the ⁠U.S. ​Food and ​Drug Administration's vaccine department.

Read More
image for news Pfizer CEO flags issues with FDA's vaccine leadership
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
PFE
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative.

Read More
image for news PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
My 5 Favorite Dividend Stocks to Buy Right Now
IBM, O, PEP, PFE, VZ
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive

It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.

Read More
image for news My 5 Favorite Dividend Stocks to Buy Right Now
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN, PFE
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive

AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.

Read More
image for news AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
PFE
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Negative

PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.

Read More
image for news Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Top High-Yield Stocks to Double Up on Right Now
PFE, UPS
Published: February 19, 2026 by: The Motley Fool
Sentiment: Positive

Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.

Read More
image for news Top High-Yield Stocks to Double Up on Right Now
Is There 25% Downside For Pfizer Stock?
PFE
Published: February 18, 2026 by: Forbes
Sentiment: Negative

Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.

Read More
image for news Is There 25% Downside For Pfizer Stock?
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
PFE
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Positive

Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.

Read More
image for news Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
PFE
Published: February 10, 2026 by: Reuters
Sentiment: Neutral

Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.

Read More
image for news Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
PFE
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
PFE
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.

Read More
image for news Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
3 High-Yield Dividend Stocks Perfect For Retirees
HPQ, PFE, VZ
Published: February 06, 2026 by: 24/7 Wall Street
Sentiment: Positive

What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks.

Read More
image for news 3 High-Yield Dividend Stocks Perfect For Retirees
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
PFE
Published: February 06, 2026 by: CNBC
Sentiment: Positive

Pfizer made one thing clear this week: It's officially back in the obesity race.

Read More
image for news Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
PFE
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Neutral

PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.

Read More
image for news Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
LLY, PFE
Published: February 04, 2026 by: The Motley Fool
Sentiment: Positive

Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.

Read More
image for news Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
PFE
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Read More
image for news Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Pfizer: Messy Q4 Earnings Mask An Improving Business
PFE
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive

Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% YoY growth, driven by oncology, signaling a successful pivot away from declining pandemic franchises. Patent cliffs—Xeljanz in 2026, Eliquis in 2028—pose risks, but PFE is aggressively advancing a 102-candidate pipeline targeting oncology, obesity, and migraine.

Read More
image for news Pfizer: Messy Q4 Earnings Mask An Improving Business
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
PFE
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative

PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.

Read More
image for news Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Silver Surges Over 15%; Pfizer Earnings Top Views
PFE, SIL, SILJ, SIVR, SLV, SLVP
Published: February 03, 2026 by: Benzinga
Sentiment: Neutral

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.

Read More
image for news Silver Surges Over 15%; Pfizer Earnings Top Views
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
PFE
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Negative

Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains a value trap as share price performance lags and patent expiries loom. Recent M&A, including Seagen and Metsera, must deliver as COVID windfall fades and major assets like Eliquis and Prevnar approach patent cliffs.

Read More
image for news Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
PFE
Published: February 03, 2026 by: CNBC Television
Sentiment: Neutral

Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.

Read More
image for news Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
2 Pharma Stocks React to Quarterly Results, Guidance
MRK, PFE
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative

Pfizer Inc (NYSE:PFE) shares are down 3.2% to trade at $25.40 at last check, despite surpassing earnings and revenue expectations for the fourth quarter.

Read More
image for news 2 Pharma Stocks React to Quarterly Results, Guidance
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
PFE
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Pfizer beats Q4 profit estimates despite COVID-19 sales decline
PFE
Published: February 03, 2026 by: Proactive Investors
Sentiment: Neutral

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, exceeding analyst expectations on adjusted earnings even as sales of its COVID-19 products fell. The pharmaceutical company's beat on profit wasn't enough to offset concerns about declining COVID-19 revenue and future growth uncertainties, with shares dropping 4.3% on Tuesday morning in New York.

Read More
image for news Pfizer beats Q4 profit estimates despite COVID-19 sales decline
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
PFE
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago.

Read More
image for news Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
PFE
Published: February 03, 2026 by: Market Watch
Sentiment: Neutral

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.

Read More
image for news Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand
PFE
Published: February 03, 2026 by: WSJ
Sentiment: Negative

Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Read More
image for news Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

About Pfizer Inc. (PFE)

  • IPO Date 1972-06-01
  • Website https://www.pfizer.com
  • Industry Drug Manufacturers - General
  • CEO Albert Bourla
  • Employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.